NVE Corporation NVEC

Set alert

Price alert · NVEC

All alert types
77.43 USD +0.85 +1.11%

As of Nov 2, 1:57 PM ET

Bid
77.13 × 2
Ask
77.71 × 2
77.19 Day range 80.31
57.21 52-week range 135.00
YTD
+30.51%
1 year
+12.14%
Open
77.90
Prev close
76.58
Mkt cap
376.34M
Vol
46.73K
Avg vol
128.54K
EPS
3.69
P/E
21.05
Div yield
4.88%
More statistics
Low
77.19
High
80.31
Forward P/E
28.59
Beta
1.13
Short ratio
5.61
Inst. own
69.61%
Dividend
4.00
Ex-div date
Nov 3, 2024
Earnings
Jan 15, 2025
50-d avg
78.00
200-d avg
79.04
1y target
0.00

1Y chart

Chart tools
Interval

Events in this range
  • Nov 3, 2025Dividend: 1
  • Feb 2, 2026Dividend: 1
  • May 18, 2026Dividend: 1
  • Aug 3, 2026Dividend: 1
  • Nov 2, 2026Dividend: 1
Signals (61)
NameDateAgo
SMA: BearishOct 22, 20261 week ago
RSI: OversoldOct 22, 20261 week ago
SMA: BearishOct 14, 20262 weeks ago
MACD: Sell SignalOct 14, 20262 weeks ago
SMA: BullishSep 25, 20261 month ago
SMA: BearishSep 24, 20261 month ago
SMA: BullishSep 22, 20261 month ago
MACD: Buy SignalSep 18, 20261 month ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BearishAug 24, 20262 months ago
MACD: Sell SignalAug 13, 20262 months ago
SMA: BullishJul 23, 20263 months ago
MACD: Buy SignalJul 23, 20263 months ago
RSI: OverboughtJul 23, 20263 months ago
SMA: BearishJul 7, 20263 months ago
SMA: BullishJun 25, 20264 months ago
SMA: BearishJun 24, 20264 months ago
MACD: Sell SignalJun 17, 20264 months ago
RSI: OverboughtJun 2, 20265 months ago
MACD: Buy SignalMay 27, 20265 months ago
MACD: Sell SignalMay 18, 20265 months ago
RSI: OverboughtMay 11, 20265 months ago
MACD: Buy SignalMay 1, 20266 months ago
MACD: Sell SignalApr 29, 20266 months ago
RSI: OverboughtApr 9, 20266 months ago
MACD: Buy SignalApr 2, 20267 months ago
SMA: BullishApr 1, 20267 months ago
SMA: BullishApr 1, 20267 months ago
SMA: BearishMar 18, 20267 months ago
SMA: BearishMar 18, 20267 months ago
MACD: Sell SignalMar 18, 20267 months ago
SMA: BullishMar 16, 20267 months ago
MACD: Buy SignalMar 16, 20267 months ago
SMA: BearishMar 13, 20267 months ago
MACD: Sell SignalMar 13, 20267 months ago
MACD: Buy SignalMar 11, 20267 months ago
SMA: BullishMar 10, 20267 months ago
MACD: Sell SignalMar 6, 20268 months ago
SMA: BearishMar 5, 20268 months ago
SMA: BullishFeb 24, 20268 months ago
MACD: Buy SignalFeb 24, 20268 months ago
SMA: BearishFeb 12, 20268 months ago
SMA: BullishFeb 11, 20268 months ago
SMA: BearishFeb 3, 20269 months ago
SMA: BearishFeb 2, 20269 months ago
MACD: Sell SignalFeb 2, 20269 months ago
RSI: OverboughtJan 22, 20269 months ago
SMA: BullishJan 16, 20269 months ago
SMA: BullishJan 14, 20269 months ago
MACD: Buy SignalJan 9, 20269 months ago
SMA: BearishDec 22, 202510 months ago
MACD: Sell SignalDec 22, 202510 months ago
SMA: BearishDec 19, 202510 months ago
RSI: OverboughtDec 10, 202510 months ago
SMA: BullishDec 4, 202511 months ago
SMA: BullishDec 4, 202511 months ago
MACD: Buy SignalNov 26, 202511 months ago
RSI: OversoldNov 17, 202511 months ago
SMA: BearishNov 3, 202512 months ago
SMA: BearishNov 3, 202512 months ago

Discussion (2)

Sign in to join the discussion

VICKY HANUKA NVEC 3 years ago #1

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.